open access

Vol 78, No 4 (2010)
ORIGINAL PAPERS
Published online: 2010-07-08
Submitted: 2013-02-22
Get Citation

The influence of inflammatory process on the ventilatory impairment in patients with stable chronic obstructive pulmonary disease

Krystyna Komnata
Pneumonol Alergol Pol 2010;78(4):271-278.

open access

Vol 78, No 4 (2010)
ORIGINAL PAPERS
Published online: 2010-07-08
Submitted: 2013-02-22

Abstract


Introduction: At present, COPD is known to be a systemic disease resulting from generalized inflammation which affects the function of many organs. Generalized inflammation is recognized from increased serum concentration of inflammatory cytokines. The aim of the present study was to investigate the influence of inflammatory process on the respiratory impairment in patients with stable chronic obstructive pulmonary disease.
Material and methods: A group of 60 stable COPD patients (GOLD stages I-IV) participated in the study. Inclusion criteria were: confirmed diagnosis of chronic obstructive pulmonary disease, clinical stable state, established treatment which had not been changed for at least 3 months prior to the study or in the course of the study. Exclusion criteria included coexistence of other diseases and/or medication causing an increase of markers of inflammation. In all patients inflammatory markers (serum concentration of fibrinogen, hs-CRP, IL-6, TNF-α) were determined. In order to assess the stage of COPD, bodyplethysmography with bronchodilating test was conducted and lung hyperinflation parameters were assessed.
Results: Analysis of relationship between markers of systemic inflammation and spirometry variables revealed a significant negative correlation between the level of hs-CRP and signs of hyperinflation; IC% of predicted value (rs = -0.29; p = 0.023) and IC/TLC (rs = -0.32; p = 0.014). The IC/TLC index also tended to be related to the concentration of fibrinogen. Higher fibrinogen concentrations were associated with lower IC/TLC values, albeit without statistical significance (rs = -0.23; p = 0.074). There was a positive relationship between serum concentration of TNF-α and arterial blood carbon dioxide pressure PaCO2 (r = 0.281; p = 0.03) as well as right ventricle systolic pressure RVSP in echocardiography (r = 0.332; p = 0.01).
Conclusions: Severity of hyperinflation progression may be associated with the increase of inflammatory process in patients with stable COPD. Inflammatory process may have an adverse affect on the respiratory system increasing significantly static lung hyperinflation.
Pneumonol. Alergol. Pol. 2010; 78, 4: 271-278

Abstract


Introduction: At present, COPD is known to be a systemic disease resulting from generalized inflammation which affects the function of many organs. Generalized inflammation is recognized from increased serum concentration of inflammatory cytokines. The aim of the present study was to investigate the influence of inflammatory process on the respiratory impairment in patients with stable chronic obstructive pulmonary disease.
Material and methods: A group of 60 stable COPD patients (GOLD stages I-IV) participated in the study. Inclusion criteria were: confirmed diagnosis of chronic obstructive pulmonary disease, clinical stable state, established treatment which had not been changed for at least 3 months prior to the study or in the course of the study. Exclusion criteria included coexistence of other diseases and/or medication causing an increase of markers of inflammation. In all patients inflammatory markers (serum concentration of fibrinogen, hs-CRP, IL-6, TNF-α) were determined. In order to assess the stage of COPD, bodyplethysmography with bronchodilating test was conducted and lung hyperinflation parameters were assessed.
Results: Analysis of relationship between markers of systemic inflammation and spirometry variables revealed a significant negative correlation between the level of hs-CRP and signs of hyperinflation; IC% of predicted value (rs = -0.29; p = 0.023) and IC/TLC (rs = -0.32; p = 0.014). The IC/TLC index also tended to be related to the concentration of fibrinogen. Higher fibrinogen concentrations were associated with lower IC/TLC values, albeit without statistical significance (rs = -0.23; p = 0.074). There was a positive relationship between serum concentration of TNF-α and arterial blood carbon dioxide pressure PaCO2 (r = 0.281; p = 0.03) as well as right ventricle systolic pressure RVSP in echocardiography (r = 0.332; p = 0.01).
Conclusions: Severity of hyperinflation progression may be associated with the increase of inflammatory process in patients with stable COPD. Inflammatory process may have an adverse affect on the respiratory system increasing significantly static lung hyperinflation.
Pneumonol. Alergol. Pol. 2010; 78, 4: 271-278
Get Citation

Keywords

chronic obstructive pulmonary disease; inflammatory cytokines; hyperinflation

About this article
Title

The influence of inflammatory process on the ventilatory impairment in patients with stable chronic obstructive pulmonary disease

Journal

Advances in Respiratory Medicine

Issue

Vol 78, No 4 (2010)

Pages

271-278

Published online

2010-07-08

Bibliographic record

Pneumonol Alergol Pol 2010;78(4):271-278.

Keywords

chronic obstructive pulmonary disease
inflammatory cytokines
hyperinflation

Authors

Krystyna Komnata

References (40)
  1. Soriano JB, Zielinski J, Price D. Screening for and early detection of chronic obstructive pulmonary disease. Lancet. 2009; 374(9691): 721–732.
  2. Spurzem JR, Rennard SI. Pathogenesis of COPD. Semin Respir Crit Care Med. 2005; 26(2): 142–153.
  3. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009; 374(9691): 733–743.
  4. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease. www.goldcopd.org.2008 (2008).
  5. Balasubramanian VP, Varkey B. Chronic obstructive pulmonary disease: effects beyond the lungs. Curr Opin Pulm Med. 2006; 12(2): 106–112.
  6. de Torres JP, Cordoba-Lanus E, López-Aguilar C, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J. 2006; 27(5): 902–907.
  7. Mueller-Anneling LJ, O'Neill ME, Thorne PS. Biomonitoring for assessment of organic dust-induced lung inflammation. Eur Respir J. 2006; 27(6): 1096–1102.
  8. Pavord ID, Birring SS, Berry M, et al. Multiple inflammatory hits and the pathogenesis of severe airway disease. Eur Respir J. 2006; 27(5): 884–888.
  9. Chazan R. Diagnostyka obrazowa układu oddechowego. In: Chazan R. ed. Pneumonologia praktyczna. a-medica Press, Bielsko Biała 2005: 151.
  10. Sciurba F.C. Inflammation in COPD. Medscape Pulmonary Medicine. www.medscape.com/viewarticle/ (2005).
  11. Bouros D, Kottakis J, Gros V, et al. Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV1 reversibility. Current Medical Research and Opinion. 2004; 20(5): 581–586.
  12. Diaz O, Villafranca C, Ghezzo H, et al. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur Respir J. 2000; 16(2): 269–275.
  13. Di Marco F, Milic-Emili J, Boveri B, et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J. 2003; 21(1): 86–94.
  14. Newton MF, O'Donnell DE, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest. 2002; 121(4): 1042–1050.
  15. Santus P, Centanni S, Verga M, et al. Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflation. Respir Med. 2006; 100(7): 1277–1281.
  16. Pecchiari M, Pelucchi A, D'Angelo E, et al. Effect of heliox breathing on dynamic hyperinflation in COPD patients. Chest. 2004; 125(6): 2075–2082.
  17. Reid R, Díaz O, Jorquera J, et al. The six minute walking test elicits lung hyperinflation in patients with severe chronic obstructive lung disease. Rev Med Chil. 2001; 129(10): 1171–1179.
  18. Vogiatzis I, Nanas S, Kastanakis E, et al. Dynamic hyperinflation and tolerance to interval exercise in patients with advanced COPD. Eur Respir J. 2004; 24(3): 385–390.
  19. Broekhuizen R, Wouters EFM, Creutzberg EC, et al. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax. 2006; 61(1): 17–22.
  20. Wouters EFM. The systemic face of airway diseases: the role of C-reactive protein. Eur Respir J. 2006; 27(5): 877–879.
  21. Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost. 2000; 84(2): 210–215.
  22. Sin DD, Man SFP. Skeletal muscle weakness, reduced exercise tolerance, and COPD: is systemic inflammation the missing link? Thorax. 2006; 61(1): 1–3.
  23. Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996; 153(2): 530–534.
  24. de Godoy I, Donahoe M, Calhoun WJ, et al. Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med. 1996; 153(2): 633–637.
  25. Joppa P, Petrasova D, Stancak B, et al. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest. 2006; 130(2): 326–333.
  26. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Eur Respir J. 1993; 6 Suppl 16: 5–40.
  27. Batura-Gabryel H. Naturalny przebieg POChP a współistnienie innych chorób. Medycyna po Dyplomie. 2008(supl. 1): 16–21.
  28. Barnes PJ. New approaches to COPD. European Respiratory Review. 2005; 14(94): 2–11.
  29. Pinto-Plata VM, Müllerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006; 61(1): 23–28.
  30. Sin DD. Why Are Patients With Chronic Obstructive Pulmonary Disease at Increased Risk of Cardiovascular Diseases?: The Potential Role of Systemic Inflammation in Chronic Obstructive Pulmonary Disease. Circulation. 2003; 107(11): 1514–1519.
  31. Gan WQ, Man SFP, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004; 59(7): 574–580.
  32. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet. 2007; 370(9589): 797–799.
  33. Agusti A, Soriano JB. Dynamic hyperinflation and pulmonary inflammation: a potentially relevant relationship? European Respiratory Review. 2006; 15(100): 68–71.
  34. Continuous or Nocturnal Oxygen Therapy in Hypoxemic Chronic Obstructive Lung Disease. Annals of Internal Medicine. 1980; 93(3): 391–398.
  35. Sevenoaks MJ, Stockley RA. Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity--a common inflammatory phenotype? Respir Res. 2006; 7: 70.
  36. Torbicki A, Kurzyna M. Nadciśnienie płucne. In: Szczeklik A, Kurzyna M. ed. Choroby wewnętrzne. T. 1. Medycyna Praktyczna, Kraków 2005: 351–353.
  37. Agustí AGN, Sauleda J, Miralles C, et al. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002; 166(4): 485–489.
  38. Frangogiannis NG, Lindsey ML, Michael LH, et al. Resident Cardiac Mast Cells Degranulate and Release Preformed TNF- , Initiating the Cytokine Cascade in Experimental Canine Myocardial Ischemia/Reperfusion. Circulation. 1998; 98(7): 699–710.
  39. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol. 1998; 274: R577–R595.
  40. Satoh M, Shimoda Y, Akatsu T, et al. Elevated circulating levels of heat shock protein 70 are related to systemic inflammatory reaction through monocyte Toll signal in patients with heart failure after acute myocardial infarction. Eur J Heart Fail. 2006; 8(8): 810–815.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl